Angiotensin-neprilysin inhibition in acute decompensated heart failure
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Acute decompensated heart failure accounts for more than 1 million hospitalizations in the United States annually. Whether the initiation of sacubitril-valsartan therapy is safe and effective among patients who are hospitalized for acute decompensated heart failure is unknown. METHODS: We enrolled patients with heart failure with reduced ejection fraction who were hospitalized for acute decompensated heart failure at 129 sites in the United States. After hemodynamic stabilization, patients were randomly assigned to receive sacubitril-valsartan (target dose, 97 mg of sacubitril with 103 mg of valsartan twice daily) or enalapril (target dose, 10 mg twice daily). The primary efficacy outcome was the time-averaged proportional change in the N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration from baseline through weeks 4 and 8. Key safety outcomes were the rates of worsening renal function, hyperkalemia, symptomatic hypotension, and angioedema. RESULTS: Of the 881 patients who underwent randomization, 440 were assigned to receive sacubitril-valsartan and 441 to receive enalapril. The time-averaged reduction in the NT-proBNP concentration was significantly greater in the sacubitril-valsartan group than in the enalapril group; the ratio of the geometric mean of values obtained at weeks 4 and 8 to the baseline value was 0.53 in the sacubitril-valsartan group as compared with 0.75 in the enalapril group (percent change, -46.7% vs. -25.3%; ratio of change with sacubitril-valsartan vs. enalapril, 0.71; 95% confidence interval [CI], 0.63 to 0.81; P<0.001). The greater reduction in the NT-proBNP concentration with sacubitril-valsartan than with enalapril was evident as early as week 1 (ratio of change, 0.76; 95% CI, 0.69 to 0.85). The rates of worsening renal function, hyperkalemia, symptomatic hypotension, and angioedema did not differ significantly between the two groups. CONCLUSIONS: Among patients with heart failure with reduced ejection fraction who were hospitalized for acute decompensated heart failure, the initiation of sacubitril-valsartan therapy led to a greater reduction in the NT-proBNP concentration than enalapril therapy. Rates of worsening renal function, hyperkalemia, symptomatic hypotension, and angioedema did not differ significantly between the two groups. (Funded by Novartis; PIONEER-HF ClinicalTrials.gov number, NCT02554890 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, one-third of patients enrolled did not have a history of HF and just more than half had no previous ACEI or ARB use.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [8]
In the citing paper
“In-hospital initiation of sacubitril-valsartan resulted in a significantly greater proportional reduction in NT-proBNP compared with enalapril at weeks 4 and from baseline (mean time-averaged change in NT-proBNP, −46.7% vs 25.3%).”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [8]
In the citing paper
“This change was consistent across all subgroups, including those without previous HF and those who were RASi-naive.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [8]
In the citing paper
“In the PIONEER-HF study it was noted that in patients admitted with acute decompensated HF and reduced ejection fraction, 65% had a history of HF but only 10% were receiving an MRA at the time of admission.8”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [8]
Citations
Cites
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000509 · Cited by 3,109
The Global Health and Economic Burden of Hospitalizations for Heart Failure
Ambrosy, A. P., Fonarow, G. C., Butler, J., Chioncel, O., Greene, S. J., Vaduganathan, M., Nodari, S., Lam, C. S. P., Sato, N., Shah, A. N., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.053 · Cited by 2,046
Self-citationGreen, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2013) · European Journal of Heart Failure · doi:10.1093/eurjhf/hft052 · Cited by 457
Senni, M., McMurray, J. J. V., Wachter, R., McIntyre, H. F., Reyes, A., Majercak, I., Andreka, P., Shehova-Yankova, N., Anand, I., Yilmaz, M. B., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.548 · Cited by 236
Velazquez, E. J., Morrow, D. A., DeVore, A. D., Ambrosy, A. P., Duffy, C. I., McCague, K., Hernandez, A. F., Rocha, R. A., & Braunwald, E. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.01.004 · Cited by 76
Self-citationAmbrosy, A. P., Mentz, R. J., Fiuzat, M., Cleland, J. G. F., Greene, S. J., O’Connor, C. M., Teerlink, J. R., Zannad, F. M., & Solomon, S. D. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1159 · Cited by 57
Self-citation
Cited by
Items 101–200 of 999
Srivastava, P. K., DeVore, A. D., Hellkamp, A. S., Thomas, L., Albert, N. M., Butler, J., Patterson, J. H., Spertus, J. A., Williams, F. B., Duffy, C. I., et al. (2021) · JACC: Heart Failure · doi:10.1016/j.jchf.2020.08.017 · Cited by 71
Self-citationRenal protection in chronic heart failure: focus on sacubitril/valsartan
Pontremoli, R., Borghi, C., & Filardi, P. P. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvab030 · Cited by 80
Gaziano, T. A., Fonarow, G. C., Velazquez, E. J., Morrow, D. A., Braunwald, E., & Solomon, S. D. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.2822 · Cited by 70
Self-citationPotential pitfalls when interpreting plasma BNP levels in heart failure practice
Nishikimi, T., & Nakagawa, Y. (2021) · Journal of Cardiology · doi:10.1016/j.jjcc.2021.05.003 · Cited by 81
NT-proBNP and high intensity care for acute heart failure: the STRONG-HF trial
Adamo, M., Pagnesi, M., Mebazaa, A., Davison, B. A., Edwards, C., Tomasoni, D., Arrigo, M., Barros, M., Biegus, J., Čelutkienė, J., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad335 · Cited by 75
Senni, M., Wachter, R., Witte, K. K., Straburzyńska‐Migaj, E., Bělohlávek, J., Fonseca, C., Mueller, C. E., Lonn, E., Chakrabarti, A., Bao, W., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1670 · Cited by 77
Mechanisms and Models in Heart Failure: A Translational Approach
Mann, D. L., & Felker, G. M. (2021) · Circulation Research · doi:10.1161/circresaha.121.318158 · Cited by 84
Mitsas, A. C., Elzawawi, M., Mavrogeni, S. I., Boekels, M., Khan, A. A., Eldawy, M., Stamatakis, I., Kouris, D., Daboul, B., Gunkel, O., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11237041 · Cited by 92
Tan, N. Y. L., Sangaralingham, L. R., Sangaralingham, S. J., Yao, X., Shah, N. D., & Dunlay, S. M. (2019) · JACC Heart Failure · doi:10.1016/j.jchf.2019.08.003 · Cited by 74
Teerlink, J. R., Díaz, R., Felker, G. M., McMurray, J. J. V., Metra, M., Solomon, S. D., Adams, K. F., Anand, I. S., Arias‐Mendoza, A., Biering‐Sørensen, T., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.2015 · Cited by 68
Thrombolysis In Myocardial Infarction (TIMI) Study Group
Sabatine, M. S., & Braunwald, E. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.01.060 · Cited by 75
Medicare Coverage and Out-of-Pocket Costs of Quadruple Drug Therapy for Heart Failure
Faridi, K. F., Dayoub, E. J., Ross, J. S., Dhruva, S. S., Ahmad, T., & Desai, N. R. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.04.031 · Cited by 69
Kimmoun, A., Cotter, G., Davison, B., Takagi, K., Addad, F., Celutkiene, J., Chioncel, O., Solal, A. C., Diaz, R., Damasceno, A., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1575 · Cited by 63
Tromp, J., Ouwerkerk, W., Teng, T. K., Cleland, J. G. F., Bamadhaj, S., Angermann, C. E., Dahlström, U., Tay, W. T., Dickstein, K., Ertl, G., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac103 · Cited by 69
New Insight in Cardiorenal Syndrome: From Biomarkers to Therapy
Gallo, G., Lanza, O., & Savoia, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065089 · Cited by 84
Recent successes in heart failure treatment
Lam, C. S. P., Docherty, K. F., Ho, J. E., McMurray, J. J. V., Myhre, P. L., & Omland, T. (2023) · Nature Medicine · doi:10.1038/s41591-023-02567-2 · Cited by 71
Ndumele, C. E., Rodríguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M. S., Bangalore, S., Bozkurt, B., Breathett, K. K., Clarke, S. L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001453 · Cited by 160
Self-citationHeidenreich, P. A., Fonarow, G. C., Breathett, K. K., Jurgens, C. Y., Pisani, B., Pozehl, B., Spertus, J. A., Taylor, K. G., Thibodeau, J. T., Yancy, C. W., et al. (2020) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/hcq.0000000000000099 · Cited by 70
Bellis, A., Mauro, C., Barbato, E., Ceriello, A., Cittadini, A., & Morisco, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020775 · Cited by 61
Spannella, F., Marini, M., Giulietti, F., Rosettani, G., Francioni, M., Perna, G. P., & Sarzani, R. (2019) · Internal and Emergency Medicine · doi:10.1007/s11739-019-02111-6 · Cited by 61
Practical outpatient management of worsening chronic heart failure
Girerd, N., Mewton, N., Tartière, J., Guijarro, D., Jourdain, P., Damy, T., Lamblin, N., Bayés‐Genís, A., Pellicori, P., Januzzi, J. L., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2503 · Cited by 67
Schnell, O., Standl, E., Catrinoiu, D., Genovese, S., Lalic, N., Skra, J., Valensi, P., & Ceriello, A. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0357-x · Cited by 59
Li, L., Lou, Q., Liu, G., Lv, J., Yun, F., Li, T., Yang, W. J., Zhao, H., Zhang, L., Bai, N., et al. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173120 · Cited by 63
Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial
Berg, D. D., Samsky, M. D., Velazquez, E. J., Duffy, C. I., Gurmu, Y., Braunwald, E., Morrow, D. A., & DeVore, A. D. (2021) · Circulation Heart Failure · doi:10.1161/circheartfailure.120.007034 · Cited by 59
Self-citationCarnicelli, A., Lippmann, S., Greene, S. J., Mentz, R. J., Greiner, M. A., Hardy, N. C., Hammill, B. G., Shen, X., Yancy, C. W., Peterson, P. N., et al. (2021) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2021.03.012 · Cited by 59
Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events
Pitt, B., Bhatt, D. L., Szarek, M. J., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.05.026 · Cited by 64
2026 ESC Guidelines for the management of heart failure
Køber, L., Adamo, M., Ruwald, A., Tomasoni, D., Anderson, L., Andersson, C., Brugts, J. J., Chioncel, O. D., Donal, E., Ferdinandy, P., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag100 · Cited by 167
Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction
Mann, D. L., Greene, S. J., Givertz, M. M., Vader, J. M., Starling, R. C., Ambrosy, A. P., Shah, P. M., McNulty, S. E., Mahr, C., Gupta, D., et al. (2020) · JACC Heart Failure · doi:10.1016/j.jchf.2020.05.005 · Cited by 57
Self-citationImplementing Guideline-Directed Medical Therapy for Heart Failure
Patolia, H. H., Khan, M. S., Fonarow, G. C., Butler, J., & Greene, S. J. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.03.430 · Cited by 65
EHRA White Paper: knowledge gaps in arrhythmia management—status 2019
Goette, A., Auricchio, A., Boriani, G., Braunschweig, F., Brugada, J., Burri, H., Camm, A. J., Crijns, H. J. G. M., Dagres, N., Deharo, J., et al. (2019) · EP Europace · doi:10.1093/europace/euz055 · Cited by 61
In-Hospital Therapy for Heart Failure With Reduced Ejection Fraction in the United States
Greene, S. J., Triana, T., Ionescu‐Ittu, R., Burne, R. M., Guérin, A., Borentain, M., Kessler, P., Tuğcu, A., DeSouza, M. M., Felker, G. M., et al. (2020) · JACC Heart Failure · doi:10.1016/j.jchf.2020.05.013 · Cited by 57
Pfeffer, M. A., Claggett, B. L., Lewis, E. F., Granger, C. B., Køber, L., Maggioni, A. P., Mann, D. L., McMurray, J. J. V., Rouleau, J. L., Solomon, S. D., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.057429 · Cited by 55
Chinese Guidelines for the Diagnosis and Treatment of Heart Failure 2024
ZHANG, S.-Y. (2025) · 老年心脏病学杂志:英文版 · doi:10.26599/1671-5411.2025.03.002 · Cited by 70
A Novel Approach to Medical Management of Heart Failure With Reduced Ejection Fraction
Miller, R. J. H., Howlett, J. G., & Fine, N. M. (2021) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.12.028 · Cited by 57
Butt, J. H., Adamson, C., Docherty, K. F., de Boer, R. A., Petrie, M. C., Inzucchi, S. E., Kosiborod, M. N., Langkilde, A. M., Lindholm, D. P., Martinez, F. A., et al. (2021) · Circulation Heart Failure · doi:10.1161/circheartfailure.121.008837 · Cited by 62
Yamamoto, K. I., & Rakugi, H. (2021) · Hypertension Research · doi:10.1038/s41440-021-00706-1 · Cited by 63
Rohde, L. E. P., Zimerman, A., Vaduganathan, M., Claggett, B. L., Packer, M., Desai, A. S., Zile, M. R., Rouleau, J. L., Swedberg, K. B., Lefkowitz, M. P., et al. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.4427 · Cited by 61
Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Treatment
Youn, J., Kim, D., Cho, J. Y., Cho, D., Park, S. M., Jung, M., Hyun, J., Cho, H., Park, S., Choi, J., et al. (2023) · International Journal of Heart Failure · doi:10.36628/ijhf.2023.0011 · Cited by 58
Colchicine in acutely decompensated heart failure: the COLICA trial
Pascual-Figal, D. A., Núñez, J. E., Pérez-Martínez, M. T., González‐Juanatey, J. R., Urquía, M. T., Llàcer, P., Delgado, J. F., Villar, S., Mirabet, S., Aimo, A., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae538 · Cited by 63
Skouri, H. N., Girerd, N., Monzo, L., Petrie, M. C., Böhm, M., Adamo, M., Müllens, W., Savarese, G., Yılmaz, M. B., Amir, O., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3618 · Cited by 60
Carnicelli, A., Li, Z., Greiner, M. A., Lippmann, S., Greene, S. J., Mentz, R. J., Hardy, N. C., Blumer, V. L., Shen, X., Yancy, C. W., et al. (2021) · JACC Heart Failure · doi:10.1016/j.jchf.2021.06.018 · Cited by 55
Brownell, N. K., Ziaeian, B., & Fonarow, G. C. (2021) · Cardiac failure review · doi:10.15420/cfr.2021.18 · Cited by 57
Ambrosy, A. P., D, E. B. M., Morrow, D. A., DeVore, A. D., McCague, K., Meng, X., Duffy, C. I., Rocha, R., & Velazquez, E. J. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.06.073 · Cited by 50
Self-citationRezq, A., Saad, M. S., & Nozahi, M. E. (2021) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.12.037 · Cited by 51
Drug Layering in Heart Failure
Rosano, G. M. C., Allen, L. A., Abdin, A., Lindenfeld, J. M., O’Meara, E., Lam, C. S. P., Lancellotti, P., Savarese, G., Gottlieb, S. S., Teerlink, J. R., et al. (2021) · JACC Heart Failure · doi:10.1016/j.jchf.2021.06.011 · Cited by 55
Greene, S. J., Ezekowitz, J. A., Anstrom, K. J., Demyanenko, V., Givertz, M. M., Piña, I. L., O’Connor, C. M., Koglin, J., Roessig, L., Hernandez, A. F., et al. (2022) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2022.02.011 · Cited by 49
Pinilla-Vera, M., Hahn, V. S., & Kass, D. A. (2019) · Circulation Research · doi:10.1161/circresaha.119.313682 · Cited by 55
Wang, C. C., Wu, C., Tsai, M., Lee, C., Huang, W. C., Chou, H., Huang, J. L., Chi, N., Yen, H., Tzeng, B., et al. (2019) · PubMed Central · doi:10.6515/acs.201905_35(3).20190422a · Cited by 54
Rosano, G. M. C., Vitale, C., Adamo, M., & Metra, M. (2021) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001221 · Cited by 55
New perspectives and future directions in the treatment of heart failure
Pellicori, P., Khan, M. J., Graham, F. J., & Cleland, J. G. F. (2019) · Heart Failure Reviews · doi:10.1007/s10741-019-09829-7 · Cited by 56
Butler, J., Siddiqi, T. J., Filippatos, G. S., Ferreira, J. P., Pocock, S., Zannad, F. M., & Anker, S. D. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2420 · Cited by 50
JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Kitai, T., Kohsaka, S., Kato, T., Kato, E. T., Sato, K., TERAMOTO, K., Yaku, H., Akiyama, E., Ando, M., Izumi, C., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.02.014 · Cited by 68
Hulot, J., Trochu, J., Donal, E., Galinier, M., Logeart, D., de Groote, P., & Juillière, Y. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1937121 · Cited by 54
Schnell, O., Standl, E., Catrinoiu, D., Itzhak, B., Lalic, N. M., Rahelić, D., Škrha, J., Valensi, P. E., & Ceriello, A. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0822-4 · Cited by 53
Consensus statement on the current pharmacological prevention and management of heart failure
Sindone, A. P., Pasquale, C. G. D., Amerena, J. V., Burdeniuk, C., Chan, A., Coats, A. J. S., Hare, D. L., Macdonald, P. S., Sverdlov, A. L., & Atherton, J. J. (2022) · The Medical Journal of Australia · doi:10.5694/mja2.51656 · Cited by 49
Pulmonary hypertension and chronic kidney disease: prevalence, pathophysiology and outcomes
Zeder, K., Siew, E. D., Kovács, G., Brittain, E. L., & Maron, B. A. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00857-7 · Cited by 52
Kapelios, C. J., Lainščak, M., Savarese, G., Laroche, C., Seferovic, P. M., Ruschitzka, F. T., Coats, A. J. S., Anker, S. D., Crespo-Leiro, M. G., Filippatos, G. S., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1532 · Cited by 50
Moon, M.-G., Hwang, I., Choi, W., Cho, G., Yoon, Y. E., Park, J., Lee, S., Kim, H., & Kim, Y.-J. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13285 · Cited by 48
Senni, M., Alemayehu, W. G., Sim, D., Edelmann, F., Butler, J., Ezekowitz, J. A., Hernandez, A. F., Lam, C. S. P., O’Connor, C. M., Pieske, B. M., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2608 · Cited by 54
Arrigo, M., Biegus, J., Asakage, A., Mebazaa, A., Davison, B. A., Edwards, C., Adamo, M., Barros, M., Čelutkienė, J., Čerlinskaitė‐Bajorė, K., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2920 · Cited by 45
Angiotensin Receptor-Neprilysin Inhibition (ARNI) in Heart Failure
Greenberg, B. (2020) · International Journal of Heart Failure · doi:10.36628/ijhf.2020.0002 · Cited by 55
Recent advances in the pharmacological therapy of chronic heart failure: Evidence and guidelines
Tsutsui, H. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108185 · Cited by 47
Asakura, M., Ito, S., Yamada, T., Saito, Y., Kimura, K., Yamashina, A., Hirayama, A., Kobayashi, Y., Hanatani, A., Tsujimoto, M., et al. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa132 · Cited by 44
Acute heart failure: current pharmacological treatment and perspectives
Deniau, B., Costanzo, M. R., Sliwa, K. S., Asakage, A., Müllens, W., & Mebazaa, A. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad617 · Cited by 53
Driving success in personalized medicine through AI-enabled computational modeling
Chakravarty, K., Antontsev, V. G., Bundey, Y., & Varshney, J. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.02.007 · Cited by 48
Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR Trial
Reddy, Y. N. V., Butler, J., Anstrom, K. J., Blaustein, R. O., Bonaca, M. P., Corda, S., Ezekowitz, J. A., Lam, C. S. P., Lewis, E. F., Lindenfeld, J., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3501 · Cited by 52
Li, X., Zhu, Q., Wang, Q., Zhang, Q., Zheng, Y., Wang, L., & Jin, Q. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-06995-x · Cited by 41
Critical Role of Neprilysin in Kidney Angiotensin Metabolism
Kaltenecker, C. C., Domenig, O., Kopecky, C., Antlanger, M., Poglitsch, M., Berlakovich, G. A., Kain, R., Stegbauer, J., Rahman, M., Hellinger, R., et al. (2020) · Circulation Research · doi:10.1161/circresaha.119.316151 · Cited by 44
Packer, M., Januzzi, J. L., Ferreira, J. P., Anker, S. D., Butler, J., Filippatos, G. S., Pocock, S., Brueckmann, M., Jamal, W., Cotton, D., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2256 · Cited by 50
Vericiguat for Heart Failure with Reduced Ejection Fraction
Lombardi, C., Cimino, G., Pagnesi, M., Dell’Aquila, A., Tomasoni, D., Ravera, A., Inciardi, R. M., Carubelli, V., Vizzardi, E., Nodari, S., et al. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01580-6 · Cited by 47
Acute Heart Failure After Non-Cardiac Surgery: Incidence, Phenotypes, Determinants and Outcomes
Gualandro, D. M., Puelacher, C., Chew, M. S., Andersson, H., Buse, G. L., Glarner, N., Mueller, D., Cardozo, F. A. M., Burri‐Winkler, K., Mork, C., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2773 · Cited by 44
Zhang, J., Du, L., Qin, X., & Guo, X. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.024449 · Cited by 46
The year in cardiology 2018: heart failure
Cleland, J. G. F., van Veldhuisen, D. J., & Ponikowski, P. P. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz010 · Cited by 42
From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5)
Leong, D. P., McMurray, J. J. V., Joseph, P. G., & Yusuf, S. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.04.068 · Cited by 46
Murphy, S., PRESCOTT, M. F., Maisel, A. S., Butler, J., Piña, I. L., Felker, G. M., Ward, J. H., WILLIAMSON, K. M., Camacho, A., Kandanelly, R. R., et al. (2021) · Circulation Heart Failure · doi:10.1161/circheartfailure.120.008410 · Cited by 43
Sacubitril/Valsartan in Heart Failure: Efficacy and Safety in and Outside Clinical Trials
Abdin, A., Schulz, M., Riemer, U., Hadëri, B., Wachter, R., Laufs, U., Bauersachs, J. K., Kindermann, I., Vukadinović, D., & Böhm, M. (2022) · ESC Heart Failure · doi:10.1002/ehf2.14097 · Cited by 51
Pascual-Figal, D., Wachter, R., Senni, M., Bao, W., Noè, A., Schwende, H., Butylin, D., Prescott, M. F., Gniot, J., Mozheiko, M., et al. (2020) · JACC: Heart Failure · doi:10.1016/j.jchf.2020.05.012 · Cited by 38
“Copyright with sacubitril/valsartan versus enalapril, with differences observed as early as 1 week following initiation of in-hospital therapy (4).”
BackgroundResultInfluentialUpdates in Cardiorenal Syndrome
McCallum, W. I., & Testani, J. M. (2023) · Medical Clinics of North America · doi:10.1016/j.mcna.2023.03.011 · Cited by 52
Polypharmacy in Older Heart Failure Patients: a Multidisciplinary Approach
Sukumar, S., Orkaby, A. R., Schwartz, J. B., Marcum, Z. A., Januzzi, J. L., Vaduganathan, M., & Warraich, H. J. (2022) · Current Heart Failure Reports · doi:10.1007/s11897-022-00559-w · Cited by 41
Ghazi, L., Yamamoto, Y., Fuery, M. A., O’Connor, K., Sen, S., Samsky, M. D., Riello, R. J., Dhar, R., Huang, J., Olufade, T. O., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad512 · Cited by 47
Self-citationEfficacy and safety of sacubitril/valsartan by dose level achieved in the PIONEER-HF trial
Berg, D. D., Braunwald, E., DeVore, A. D., Lala, A., Pinney, S. P., Duffy, C. I., Gurmu, Y., Velazquez, E. J., & Morrow, D. A. (2020) · JACC: Heart Failure · doi:10.1016/j.jchf.2020.06.008 · Cited by 36
Self-citationMazzetti, S., Scifo, C., Abete, R., Margonato, D., Chioffi, M., Rossi, J., Pisani, M., Passafaro, G., Grillo, M., Poggio, D., et al. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12656 · Cited by 41
Reappraisal on pharmacological and mechanical treatments of heart failure
Liang, B., Zhao, Y.-X., Zhang, X., Liao, H.-L., & Gu, N. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01024-5 · Cited by 40
Zhang, H., Huang, T., Shen, W., Xu, X., Yang, P., Zhu, D., Fang, H., Wan, H., Wu, T., Wu, Y., et al. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12974 · Cited by 42
Treatment of HF in an Era of Multiple Therapies
Bhatt, A. S., Abraham, W. T., Lindenfeld, J., Bristow, M. R., Carson, P. E., Felker, G. M., Fonarow, G. C., Greene, S. J., Psotka, M. A., Solomon, S. D., et al. (2020) · JACC Heart Failure · doi:10.1016/j.jchf.2020.10.014 · Cited by 38
Dixit, N. M., Shah, S. P., Ziaeian, B., Fonarow, G. C., & Hsu, J. J. (2021) · US Cardiology Review · doi:10.15420/usc.2020.29 · Cited by 45
Metra, M., Pagnesi, M., Claggett, B. L., Díaz, R., Felker, G. M., McMurray, J. J. V., Solomon, S. D., Bonderman, D., Fang, J. C.-T., Fonseca, C., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac293 · Cited by 39
Cox, Z. L., Nandkeolyar, S., Johnson, A. J., Lindenfeld, J. M., & Rali, A. S. (2022) · Cardiac failure review · doi:10.15420/cfr.2022.08 · Cited by 41
Nishikimi, T., & Nakagawa, Y. (2022) · Biology · doi:10.3390/biology11071034 · Cited by 55
D’Amario, D., Rodolico, D., Delvinioti, A., Laborante, R., Iacomini, C., Masciocchi, C., Restivo, A., Ciliberti, G., Galli, M., Paglianiti, D. A., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.029071 · Cited by 47
Sokos, G. G., & Raina, A. (2020) · Vascular Health and Risk Management · doi:10.2147/vhrm.s197291 · Cited by 36
Feng, Y., Yin, Y., Deng, R., & Li, H. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13243 · Cited by 38
Cardiac foetal reprogramming: a tool to exploit novel treatment targets for the failing heart
van der Pol, A., Hoes, M. F., de Boer, R. A., & van der Meer, P. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13094 · Cited by 44
Nielsen, E. E., Feinberg, J. B., Bu, F.-L., Olsen, M. H., Raymond, I. E., Steensgaard-Hansen, F., & Jakobsen, J. C. (2020) · Open Heart · doi:10.1136/openhrt-2020-001294 · Cited by 41
Chioncel, O. D., Davison, B. A., Adamo, M., Antohi, E., Arrigo, M., Barros, M., Biegus, J., Čerlinskaitė‐Bajorė, K., Čelutkienė, J., Solal, A. C., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.3039 · Cited by 40
ARNi: A Novel Approach to Counteract Cardiovascular Diseases
Volpe, M., Rubattu, S. D., & Battistoni, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092092 · Cited by 40
Health‐related quality of life outcomes in PARAGON‐HF
Chandra, A., Polanczyk, C. A., Claggett, B. L., Vaduganathan, M., Packer, M., Lefkowitz, M. P., Rouleau, J. L., Liu, J., Shi, V. C., Schwende, H., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2738 · Cited by 33
Advances in management of heart failure
Heidenreich, P. A., & Sandhu, A. T. (2024) · BMJ · doi:10.1136/bmj-2023-077025 · Cited by 44
Abós, C. M., Rivas‐Lasarte, M., Pàmies, J., Fluvià-Brugués, P., Solé‐González, E., Mirabet, S., López, L., Brossa, V., Pirla, M. J., Mesado, N., et al. (2019) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-019-06858-0 · Cited by 33
Neprilysin: A Potential Therapeutic Target of Arterial Hypertension?
Salazar, J. J., Rojas, J., Cano, C., Pérez, J. L., Ramírez, P., Carrasquero, R., Torres, W., Díaz, C. I. E., Chacín, M., & Bermúdez, V. (2019) · Current Cardiology Reviews · doi:10.2174/1573403x15666190625160352 · Cited by 37
Metadata
- Authors
- Velazquez, E. J., Morrow, D. A., DeVore, A. D., Duffy, C. I., Ambrosy, A. P., McCague, K., Rocha, R., & Braunwald, E.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (E.J.V.); the Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston (D.A.M., E.B.); Duke Clinical Research Institute, Duke University, Durham, NC (A.D.D.); Novartis Pharmaceuticals, East Hanover, NJ (C.I.D., K.M., R.R.); and the Division of Cardiology, Permanente...
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-02-07
- Volume
- 380
- Issue
- 6
- Pages
- 539-548
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899841238
- Cited by
- 1,260
- References
- 16
- Citations by year
- 2026: 74 · 2025: 139 · 2024: 136 · 2023: 215 · 2022: 199 · 2021: 189 · 2020: 171 · 2019: 128
- FWCI
- 93.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novartis Pharmaceuticals Corporation
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- acute decompensated heart failure, sacubitril/valsartan, enalapril, heart failure with reduced ejection fraction, NT-proBNP, renal function, hyperkalemia, angioedema, symptomatic hypotension, drug safety, hospitalization, hemodynamic stabilization, natriuretic peptides
- MeSH terms
- Valsartan, Acute Disease, Aged, Aminobutyrates, Angiotensin-Converting Enzyme Inhibitors, Biphenyl Compounds, Cardiac Output, Low, Dose-Response Relationship, Drug, Double-Blind Method, Drug Combinations, Enalapril, Female, Heart Failure, Humans, Male, Middle Aged, Peptide Fragments, Stroke Volume, Tetrazoles, Neprilysin, Natriuretic Peptide, Brain, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.